Diclof S.R 100

Diclof S.R 100

- Diclofenac sodium, a phenylacetic acid derivative, is a non-steroidal compound with pronounced antirheumatic, anti-inflammatory, analgesic and antipyretic properties. 
- It inhibits prostaglandin biosynthesis which plays a major role in causing inflammation, pain and fever. Medication with Diclofenac sodium can relieve the symptoms of inflammation, but can not cure the cause. In rheumatic diseases, Diclofenac sodium elicits a clinical response characterized by marked relief from signs and symptoms such as pain at rest, pain on movement, morning stiffness, and swelling of the joints, as well as by an improvement in function. 
- Diclofenac is almost completely absorbed. Food has no clinical relevant influence on the absorption and bioavailability of Diclofenac. 
- No accumulation occurs provided the recommended dosage intervals are observed even in patients suffering from renal impairment. 99.7% of  Diclofenac is bound to serum proteins. It enters the synovial fluid, and reaches higher levels in the synovial fluid than in the plasma and remain higher for up to 12 hours. 
- Diclofenac is subject to first-pass metabolism and then excreted mainly in the urine (about 65%) but also in the bile (about 35%).

- Each Capsule of DICLOF ® S.R 100 contains: 
   Diclofenac sodium     100 mg  
- Each Enteric Coated Tablet  of  DICLOF ®  50 contains: 
   Diclofenac sodium     50 mg  
- Each Enteric Coated Tablet of  DICLOF ®   25 contains:
   Diclofenac sodium     25 mg
 - Each Suppository  of  DICLOF®   25 contains:
   Diclofenac sodium     25 mg
- Each Suppository  of  DICLOF ®   12.5 contains::
   Diclofenac sodium     12.5 mg

- Hypersensitivity to Diclofenac. 
- DICLOF ® should not be given to patients with peptic ulcer and to patients who have experienced asthma, urticaria, or other allergic-type reactions caused by Aspirin or other  NSAIDs. 

- Like other NSAIDs, DICLOF ® may reduce the efficacy of diuretics. 
- Concomitant treatment with a potassium-sparing diuretic may be associated with increased serum potassium levels, which should therefore be monitored frequently. 
- Patients taking DICLOF ® and are also receiving Digoxin, Methotrexate, Cyclosporin or Lithium should be observed for potential development of the specific toxicities of these drugs. 
- Concomitant administration of other systemic NSAIDs or Glucocorticoids may increase the occurrence of side effects. 
- Cholestyramine appears to reduce the bioavailability of Diclofenac when the two drugs are given together; Colestipol produces a similar action but smaller effect. 

- Owing to the possibility of uterine inertia and/or premature closure of the ductus arteriosus, DICLOF ® should not be used in the third trimester. 
- DICLOF ® passes into breast milk, but in quantities so small to be harmful to a breast-fed infant

- DICLOF ® is generally well tolerated. The most common side effects include gastro-intestinal disturbances, headache, dizziness, Fluid retention, liver function disorders, rash and pruritis have been reported. 

* As with other NSAIDs, DICLOF ® should be used with caution:
- In patients with impaired hepatic or renal function.
- History of cardiovascular diseases and  peptic ulcer

- DICLOF ® S.R 100 mg Capsules:
   (Blisters of 10 Capsules, Pack of one blister.)
- DICLOF ® Enteric Coated Tablets 25 mg and 50 mg: 
   (Blisters of 10 enteric coated tablets, Packs of two  blisters.)
- Hospital packs of different sizes. 
- DICLOF ® Suppository  25 mg and 12.5 mg: 
   (Blisters of 5 Suppository  , Packs of one blisters.)

- Store in a dry place  at a temperature below  25oC.
- Protect from moisture and light.